Ultragenyx Pharmaceutical Inc. Form DEFA14A April 27, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

ULTRAGENYX PHARMACEUTICAL INC.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

Payment of Filing Fee (Check the appropriate box):

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form DEFA14A

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
(1)	Title of each class of securities to which transaction applies:	
(2)	Aggregate number of securities to which transaction applies:	
(2)	Denouit union on other and delains value of transaction commuted appropriate Euchemen Act Dule 0.11 (act	
(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
(4)	Proposed maximum aggregate value of transaction:	
(5)	Total fee paid:	
(3)	Total lee pale.	
Fee paid previously with preliminary materials.		
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for		
which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.		
(1)	Amount Previously Paid:	
. /		
(2)		
(2)	Form, Schedule or Registration Statement No.:	
(3)	Filing Party:	

(4) Date Filed:

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 19, 2018.

ULTRAGENYX PHARMACEUTICAL INC.

ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

NOVATO, CA 94949

Meeting Information

Meeting Type: Annual Meeting **For holders as of:** April 23, 2018

Date: June 19, 2018 **Time:** 2:00 p.m., Pacific Time **Location:** Meeting live via the Internet-please visit

www.virtualshareholdermeeting.com/RARE18

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/RARE18 and be sure to have the information that is printed in the box marked by the arrow (located on the following page).

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form DEFA14A

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Before You Vote

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2017

How to View Online:

Have the information that is printed in the box marked by the arrow (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, or proxy materials for future stockholder meetings, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com

2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

Please make the request as instructed above on or before June 5, 2018 to facilitate timely delivery.

^{*} If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow (located on the following page) in the subject line. Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor.

How To Vote

Please Choose One of the Following Voting Methods

Vote By Internet:

Before The Meeting:

Go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

During The Meeting:

Go to www.virtualshareholdermeeting.com/RARE18. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

	Voting Items	
Company Proposals		
The Board of Directors recommends that you vote FOR the		
election of the three nominees for director named below:		
Nomi	inees:	
1a.	Deborah Dunsire, M.D.	
1b.	Michael Narachi	
1c.	Clay B. Siegall, Ph.D.	
The Board of Directors recommends you vote FOR proposals 2 and 3:		
	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018.	
3. A	Advisory (non-binding) vote to approve the compensation of our named executive officers.	